For medical professionals to read and reference

Not all infected people are suitable for eradication!

• Peptic ulcer (with or without activity and history of complications);

• Lymphoma of the lymphoid tissue associated with the gastric mucosa;

• Early gastric cancer undergoes endoscopic submucosal peeling or subtotal gastrectomy;

• Have a family history of stomach cancer;

• Plan to take NSAIDs (including low-dose aspirin) for a long time;

• Hp gastritis;

• Gastric hyperplastic polyps;

• Hp-associated dyspepsia;

• Prolonged use of proton pump inhibitors;

• Unexplained iron deficiency anemia;

• Primary immune thrombocytopenia;

• Vitamin_B12 deficiency;

• Confirmed Hp infection (no eradication therapy countervaliants).
  
  

  
  

• Patients with serious diseases (systemic diseases, malignant tumors, psychiatric diseases, liver/kidney/heart and other important organ failure or more serious diseases);
• Advanced age
  .
  
  Although Hp infection is common, in fact, most infected people do not have related diseases in their lifetime, and only a small number of infected people may suffer from gastrointestinal diseases
  of varying degrees.
  
  

  Professor Cao Xiaocang

  
  
  
  

  • Chief Physician and Professor of Gastroenterology, General Hospital of Tianjin Medical University, Master Supervisor of Tianjin Medical University, Ph.
    D.
    of Peking Union Medical College and Tsinghua University School of Medicine, Postdoctoral Fellow of Texas State University School of Medicine, and Postdoctoral Visiting Scholar
    of Lille University School of Medicine, France.
    

    
    

  
  

  • Member of the Gastroenterology Committee of the Gastroenterology Branch of the Chinese Medical Association, Vice Chairman of the Youth Committee of the Behavioral Medicine Branch of the Chinese Medical Association, Member of the Clinical Epidemiology Collaborative Group of the Gastroenterology Branch of the Chinese Medical Association, Member of the Inflammatory Enterology Group of the Gastroenterology Branch of the Chinese Medical Equipment Association, Member of the Proctology Committee of the Inflammatory Bowel Disease Professional Committee of the Anorectal Physician Branch of the Chinese Medical Doctor Association, Member of the Inflammatory Bowel Disease Professional Committee of the Chinese Medical Doctor Association, Member of the Inflammatory Bowel Disease Professional Committee of the Chinese Association of Integrative Traditional and Western Medicine, Member of the Inflammatory Bowel Disease Expert Committee of the Gastroenterology Branch of the Chinese Medical Doctor Association, He is a member of the Inflammatory Bowel Disease Expert Committee of Beijing Medical Reward Foundation, a member of the Standing Committee of the Inflammatory Bowel Disease Alliance of Wu Jieping Medical Foundation, a member of the Standing Committee of the Enterologic Microecology Professional Committee of the Inflammatory Bowel Disease Alliance of the Chinese Society of Biomedical Engineering, a member of the Standing Committee of the Stem Cell Engineering Technology Branch of the Chinese Society of Biomedical Engineering, and a vice chairman of the Inflammatory Enterology Group of the Gastroenterology Branch of the Tianjin Medical Association

  
  

  • Research interests: Inflammatory bowel disease and digestive immune disease biological therapy and cell therapy, especially in the clinical application of mesenchymal stem cell transplantation
    .
    
    His research achievements have won awards from international conferences such as the American Gastroenterology Annual Conference and the European Union Gastroenterology Annual Conference, and have published dozens of papers in SCI journals and Chinese journals
    .
    

    
    
    
    

  Xie Dong

  
  
  Clinical pharmacist of Tianjin Medical University General Hospital, gastroenterology major of National Clinical Pharmacist Training Base, and MTM pharmacist certified by the American Pharmacists
  Association (APhA).
  
  References:

  
  

  [1] Huang Cuixiang, Chen Xi, Bao Yu, et al.
  Research progress on the relationship between Helicobacter pylori and gastrointestinal and parenteral diseases[J].
  Chongqing Medicine:1-8.
  

  [2] Yan Lingjun,Chen Ying,Chen Fa,et al.
  Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention:Updated Report from a Randomized Controlled Trial with 26.
  5 Years of Follow-up[J].
  Gastroenterology,2022(163):154-162.
  

  Helicobacter pylori group of Gastroenterology Branch of Chinese Medical Association.
  The Sixth National Consensus Report on Helicobacter pylori Infection Management (Non-Eradication Treatment Part)[J].
  Chinese Journal of Digestion,2022,42(5):289-303.
  

  [4] Meriyah Muguli Aishan, Chen Zhifen.
  Clinical significance of eradication of Helicobacter pylori in the prevention of gastric cancer[J].
  Journal of Wuhan University:Medical Edition,2020,41(1):65-69.
  

  Wang Bojun.
  Countervailing factors and controversy of Helicobacter pylori eradication therapy[J].
  Physician Online,2020,10(13):32-33.
  

  
  Where to see more clinical knowledge of digestive liver disease? Come to the "Doctor's Station" and take a look 👇